<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Akerblom, L.</title>
    <link>http://repub.eur.nl/res/aut/2653/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Protection of rhesus macaques from SIV infection by immunization with different experimental SIV vaccines. (Article)</title>
      <link>http://repub.eur.nl/res/pub/3510/</link>
      <pubDate>1994-11-11T00:00:00Z</pubDate>
      <description>The immunogenicity and efficacy of an inactivated whole SIVmac (32H) preparation adjuvanted with muramyl dipeptide (SIV-MDP) and a gp120-enriched SIVmac (32H) ISCOM preparation (SIV-ISCOM), were compared by immunizing four rhesus macaques (Macaca mulatta) four times with SIV-MDP and four others in the same way with SIV-ISCOM. Two monkeys immunized with whole inactivated measles virus (MV) adjuvanted with MDP (MV-MDP) and two monkeys immunized with MV-ISCOM served as controls. In the SIV-ISCOM-immunized monkeys higher SIV-specific serum antibody titres were found than in the SIV-MDP-immunized monkeys. In contrast to the MV-immunized monkeys all SIV-MDP- and SIV-ISCOM-immunized monkeys were protected against intravenous challenge 2 weeks after the last immunization with 10 median monkey infectious doses (MID50) of a cell-free SIVmac (32H) challenge stock propagated in the human T-cell line C8166. After 43 weeks the protected monkeys were reboosted and 2 weeks later rechallenged with 10 MID50 of the same virus produced in peripheral blood mononuclear cells (PBMC) from a rhesus macaque. None of these animals proved to be protected against this challenge. In a parallel experiment in which the same numbers of monkeys were immunized in the same way, the animals were challenged intravenously with 10 MID50 of PBMC from an SIVmac (32H)-infected rhesus macaque. Two out of four SIV-MDP- and two out of four SIV-ISCOM-immunized monkeys proved to be protected from SIV infection.</description>
    </item> <item>
      <title>Formation and characterization of FeLV iscoms. (Article)</title>
      <link>http://repub.eur.nl/res/pub/3361/</link>
      <pubDate>1989-01-01T00:00:00Z</pubDate>
      <description>Immunostimulating complexes (ISCOMs) have been prepared from feline leukaemia virus (FeLV) envelope proteins. The ISCOMs were characterized biochemically in SDS-polyacrylamide gel electrophoresis showing the presence of proteins of estimated molecular weights of 15,000, 27,000 and 70,000. Immunoblotting showed that both the transmembrane protein p15E and the external glycoprotein gp70 (making up the gp85 protein) were present in the ISCOM. Furthermore, a degradation product of gp70 with an estimated molecular weight of 32,000 was identified in the immunoblot. The FeLV ISCOM was shown by electron microscopy to have the characteristic cage-like structure of an ISCOM with a mean diameter of 37 nm. About 10% of the total amount of gp70 in the culture fluid was recovered in the ISCOMs. The largest loss was encountered during the sedimentation of the virus. In a preliminary immunization experiment in mice the FeLV ISCOMs elicited after a booster gave a clear-cut immune response against gp70.</description>
    </item>
  </channel>
</rss>